48 related articles for article (PubMed ID: 16533402)
1. Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells.
Weis-Banke SE; Lisle TL; Perez-Penco M; Schina A; Hübbe ML; Siersbæk M; Holmström MO; Jørgensen MA; Marie Svane I; Met Ö; Ødum N; Madsen DH; Donia M; Grøntved L; Andersen MH
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36316062
[TBL] [Abstract][Full Text] [Related]
2. Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials.
Wolchok JD; Weber JS; Hamid O; Lebbé C; Maio M; Schadendorf D; de Pril V; Heller K; Chen TT; Ibrahim R; Hoos A; O'Day SJ
Cancer Immun; 2010 Oct; 10():9. PubMed ID: 20957980
[TBL] [Abstract][Full Text] [Related]
3. HLA-A2 expression, stage, and survival in colorectal cancer.
Kiewe P; Mansmann V; Scheibenbogen C; Buhr HJ; Thiel E; Nagorsen D
Int J Colorectal Dis; 2008 Aug; 23(8):767-72. PubMed ID: 18461337
[TBL] [Abstract][Full Text] [Related]
4. [Role of MHC class I molecules in anti-tumoral mechanisms in human malignant melanoma].
Dissemond J; Grabbe S
Hautarzt; 2006 Aug; 57(8):690-6. PubMed ID: 16163561
[TBL] [Abstract][Full Text] [Related]
5. HLA-B8 association with late-stage melanoma--an immunological lesson?
Fensterle J; Trefzer U; Berger T; Andersen MH; Ugurel S; Becker JC
BMC Med; 2006 Mar; 4():5. PubMed ID: 16533402
[TBL] [Abstract][Full Text] [Related]
6. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions.
Kageshita T; Ishihara T; Campoli M; Ferrone S
Tissue Antigens; 2005 May; 65(5):419-28. PubMed ID: 15853896
[TBL] [Abstract][Full Text] [Related]
7. Modification of cytokine patterns in subjects bearing the HLA-B8,DR3 phenotype: implications for autoimmunity.
Lio D; Candore G; Romano GC; D'Anna C; Gervasi F; Di Lorenzo G; Modica MA; Potestio M; Caruso C
Cytokines Cell Mol Ther; 1997 Dec; 3(4):217-24. PubMed ID: 9740350
[TBL] [Abstract][Full Text] [Related]
8. HLA class I and class II frequencies in patients with cutaneous malignant melanoma from southeastern Spain: the role of HLA-C in disease prognosis.
Campillo JA; Martínez-Escribano JA; Muro M; Moya-Quiles R; Marín LA; Montes-Ares O; Guerra N; Sánchez-Pedreño P; Frías JF; Lozano JA; García-Alonso AM; Alvarez-López MR
Immunogenetics; 2006 Jan; 57(12):926-33. PubMed ID: 16365741
[TBL] [Abstract][Full Text] [Related]
9. Linkage disequilibrium of HLA-DR3 and HLA-DR4 with HLA-B alleles in Mexican patients with rheumatoid arthritis.
Avila-Portillo LM; Vargas-Alarcón G; Andrade F; Alarcón-Segovia D; Granados J
Clin Exp Rheumatol; 1994; 12(5):497-502. PubMed ID: 7842529
[TBL] [Abstract][Full Text] [Related]
10. Primary sclerosing cholangitis is associated to an extended B8-DR3 haplotype including particular MICA and MICB alleles.
Wiencke K; Spurkland A; Schrumpf E; Boberg KM
Hepatology; 2001 Oct; 34(4 Pt 1):625-30. PubMed ID: 11584356
[TBL] [Abstract][Full Text] [Related]
11. B-Raf specific antibody responses in melanoma patients.
Fensterle J; Becker JC; Potapenko T; Heimbach V; Vetter CS; Bröcker EB; Rapp UR
BMC Cancer; 2004 Sep; 4():62. PubMed ID: 15361259
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of constitutively active V599EBRaf.
Andersen MH; Fensterle J; Ugurel S; Reker S; Houben R; Guldberg P; Berger TG; Schadendorf D; Trefzer U; Bröcker EB; Straten Pt; Rapp UR; Becker JC
Cancer Res; 2004 Aug; 64(15):5456-60. PubMed ID: 15289355
[TBL] [Abstract][Full Text] [Related]
13. HLA-B35-restricted immune responses against survivin in cancer patients.
Reker S; Becker JC; Svane IM; Ralfkiaer E; Straten PT; Andersen MH
Int J Cancer; 2004 Mar; 108(6):937-41. PubMed ID: 14712500
[TBL] [Abstract][Full Text] [Related]
14. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes.
Benlalam H; Linard B; Guilloux Y; Moreau-Aubry A; Derré L; Diez E; Dreno B; Jotereau F; Labarrière N
J Immunol; 2003 Dec; 171(11):6283-9. PubMed ID: 14634146
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
